Other
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss
Gilead Sciences Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss decreased by 67.0% to $1.00B in Q1 2026 compared to the prior quarter. Over 5 years (FY 2020 to FY 2025), Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss shows an upward trend with a 8.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2020
Last reportedQ1 2026May 7, 2026
How to read this metric
An increase suggests capital deployment into fixed-income assets, while a decrease may indicate portfolio liquidation or maturation.
Detailed definition
This reflects the amortized cost basis of debt securities classified as available-for-sale, adjusted for credit losses b...
Peer comparison
Common in insurance and banking sectors; peers report this under 'Investments' in the balance sheet.
Metric ID:
other_debt_securities_available_for_sale_amortized_cost__1e72d5Historical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.52B | $2.49B | $2.50B | $2.54B | $2.32B | $2.33B | $2.33B | $2.35B | $2.37B | $2.40B | $2.43B | $0.00 | $1.99B | $2.01B | $3.03B | $1.00B |
| QoQ Change | — | -1.3% | +0.5% | +1.4% | -8.4% | +0.3% | -0.3% | +1.1% | +0.7% | +1.5% | +1.1% | -100.0% | — | +1.4% | +50.6% | -67.0% |
| YoY Change | — | — | — | — | -7.9% | -6.3% | -7.0% | -7.3% | +1.9% | +3.1% | +4.5% | -100.0% | — | — | — | — |
Range$0.00 – $3.03B
CAGR-21.9%
Avg YoY Growth-14.9%
Median YoY Growth-6.7%
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
- Gilead Sciences (GILD) reported debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss of $1.00B in Q1 2026.
- What is the long-term trend for Gilead Sciences's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss?
- Over 5 years (2020 to 2025), Gilead Sciences's debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss has grown at a 8.4% compound annual growth rate (CAGR), from $2.02B to $3.03B.
- What does debt securities, available-for-sale, amortized cost, excluding accrued interest, after allowance for credit loss mean?
- The historical cost of debt investments held for potential sale, adjusted for credit losses.